Approval · Notice of Compliance 37804 · 2026
ZEPZELCA: Notice of Compliance 37804
Issued June 29, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37804
- Date
- June 29, 2026
- Company
- Jazz Pharmaceuticals Ireland LimitedDublin, Dublin, Ireland
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of new indication: ZEPZELCA (lurbinectedin) is indicated in combination with atezolizumab for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZEPZELCA | Not yet assigned | — |
Medicinal ingredients
- LURBINECTEDIN 4 MG per VIAL